COI Outlined below is an approach to valuing COI for cancer (excluding intangible costs): Number of cancer Direct cost per Indirect cost per Cost of Illness = x ( + ) (COI) registrations registration registration Where: Direct cost per Direct outpatient Direct inpatient = + + Direct homecare costs registration costs costs Production lost Production lost Indirect cost per = of production x ( because of + because of ) registration illness It is extremely difficult to gather information required to estimate direct and indirect costs for each type of cancer and estimate values of production and production lost for each sector affected. In most cases, this information is not publicly available. Therefore, COI estimates have been taken from existing studies related to cancer. Rabl (2004) provides values of unit costs (i.e. per patient) that are used in France for different morbidity risks. It includes estimates for COI and willingness-to-pay (WTP) related to avoiding the suffering and inconvenience of disease. The COI includes direct and indirect costs of cancer but not the intangible costs of cancer. Intangible costs are however included in the WTP estimates. These estimates are set out in . Table 3.2 Estimated unit costs of cancer (€ 2009 prices) except for NMSC – Health endpoint Cost of Illness (COI) WTP to avoid suffering Cancer, fatal (per incident) 48,601 1,768,256 € € Cancer, non-fatal (per incident) 48,601 486,271 € € Note: Prices have been updated from USD to EUR using historical exchange rates for 2004 and updated to 2009 prices using the EU harmonised index of consumer prices (HICP). It was not possible to find an estimate for COI for each type of cancer and therefore the estimate (€ 48,601) is used for all cancers, with the exception for nonmelanoma skin cancer (NMSC) where there is a greater survival rate and costs of treatment may be less expensive. Costs for NMSC are presented in Table 3.3. Costs for NMSC are based on a simple meta-analysis of various studies examining the economic costs of NMSC. Of particular relevance was a study by Miljoministeriet (2004) in which the direct costs of NMSC
COI Outlined below is an approach to valuing COI for cancer (excluding intangible costs): Cost of Illness (COI) = Number of cancer registrations x ( Direct cost per registration + Indirect cost per registration ) Where: Direct cost per registration = Direct outpatient costs + Direct inpatient costs + Direct homecare costs Indirect cost per registration = of production x ( Production lost because of illness + Production lost because of ) It is extremely difficult to gather information required to estimate direct and indirect costs for each type of cancer and estimate values of production and production lost for each sector affected. In most cases, this information is not publicly available. Therefore, COI estimates have been taken from existing studies related to cancer. Rabl (2004) provides values of unit costs (i.e. per patient) that are used in France for different morbidity risks. It includes estimates for COI and willingness-to-pay (WTP) related to avoiding the suffering and inconvenience of disease. The COI includes direct and indirect costs of cancer but not the intangible costs of cancer. Intangible costs are however included in the WTP estimates. These estimates are set out in . Table 3.2 Estimated unit costs of cancer (€ 2009 prices) – except for NMSC Health endpoint Cost of Illness (COI) WTP to avoid suffering Cancer, fatal (per incident) € 48,601 € 1,768,256 Cancer, non-fatal (per incident) € 48,601 € 486,271 Note: Prices have been updated from USD to EUR using historical exchange rates for 2004 and updated to 2009 prices using the EU harmonised index of consumer prices (HICP). It was not possible to find an estimate for COI for each type of cancer and therefore the estimate (€ 48,601) is used for all cancers, with the exception for nonmelanoma skin cancer (NMSC) where there is a greater survival rate and costs of treatment may be less expensive. Costs for NMSC are presented in Table 3.3. Costs for NMSC are based on a simple meta-analysis of various studies examining the economic costs of NMSC. Of particular relevance was a study by Miljoministeriet (2004) in which the direct costs of NMSC
bjc2017161x2.docx